Somatostatin acetate 38916-34-6

98% up by HPLC, GMP

Product categories

New Products

Product Details

Product Information

Product name	Somatostatin acetate
Alias	Somatostatina, Somatostatine, Somatostatinum, Somatostatin, cyclic, Somatostatin-14, Aminopan, Panhibin, Somiaton
CAS No.	38916-34-6
Molecular Formula	C76H104N18O19S2
Molecular Weight	1637.87
Molecule Structure
Quality Standard	98% up by HPLC, GMP
Appearance	White powder

COA of Somatostatin Acetate

Items	Specification	Results
Appearance	White Powder	Conforms
Purity(HPLC)	> 98%	99.57%
Specific optical rotation (anhydrous and acetic acid-free substance)	-37° to -47°	-41°
Solubility	freely soluble in water and in acetic acid, practically insoluble in methylene chloride	Conforms
Related substances (HPLC)	Total impurities: NMT 2.0% Any impurity: NMT 1.0%	1.3% 0.3%
Water (Karl Fischer)	NMT 8.0 %	6.5%
Acetic acid (HPLC)	3.0% to 15.0 %	8.7%
Bacterial endotoxins	< 10IU/mg	Conforms
Assay (anhydrous and acetic acid-free substance)	95.0% to 104.0%	99.34%
Conclusion	Complies with the standard.

Usage

Function of Somatostatin Acetate

Somatostatin Acetate is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation through its interaction with G protein.

① It can inhibit the secretion of growth hormone, thyroid stimulating hormone, insulin and glucagon.

②It can inhibit the secretion of gastric acid stimulated by the test meal and 5-peptide gastrin, and can inhibit the release of pepsin and gastrin.

③It can significantly reduce visceral blood flow, reduce portal vein pressure, reduce blood flow and pressure of collateral circulation, and reduce liver blood flow.

④Reduce the secretion of the pancreas and the secretion of the small intestine and gallbladder, reduce enzyme activity, and have a protective effect on pancreatic cells.

⑤ It can affect the absorption and nutritional function of the gastrointestinal tract.

Application of Somatostatin Acetate

Somatostatin Acetate can be used for severe and acute gastric and duodenal ulcer bleeding; acute erosive or hemorrhagic gastritis severe and acute bleeding; prevention of post-pancreatic complications after pancreatic surgery; inhibition of pancreas and Adjuvant treatment for severe secretion of leaky duct after upper small intestine surgery; regulating human differentiated gastric cancer cell lines

Hot Tags : Somatostatin Somatostatin acetate Somatostatin peptide 38916-34-6 polypeptide powder polypeptide supplier

Send A Message

Related Products

LIRAGLUTIDE 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.